Effects of Secukinumab combined with Calcipotriol cream in treatment of patients with moderate to severe psoriasis
Objective:To observe effects of Secukinumab combined with Calcipotriol cream in treatment of patients with moderate to severe psoriasis.Methods:A prospective study was conducted on 68 patients with moderate to severe psoriasis admitted to the hospital from January 2021 to June 2023.According to the random number table method,they were divided into control group and observation group,34 cases in each group.The control group was treated with Calcipotriol cream,while the observation group was treated with Secukinumab on the basis of the control group.The clinical efficacy,the disappearance time of clinical symptoms,the skin barrier function indicators[sebum content,stratum corneum water content,transepidermal water loss(TEWL)]levels,the serological indicators[interleukin-2(IL-2),γ-interferon(IFN-γ)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 97.06%(33/34),which was higher than that of the control group 76.47%(26/34),and the difference was statistically significant(P<0.05).The disappearance time of clinical symptoms such as skin itching,erythema,scales and desquamation in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).The water content and sebum content of stratum corneum in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the TEWL levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of IL-2 and IFN-γ in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Secukinumab combined with Calcipotriol cream in the treatment of the patients with moderate to severe psoriasis can improve the clinical efficacy,shorten the disappearance time of clinical symptoms,and improve the skin barrier function indicator and the serological indicator levels.Moreover,it is superior to simple Calcipotriol cream treatment.
NETL
NSTL
万方数据
